Arie Zauberman
Weizmann Institute of Science
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Arie Zauberman.
The EMBO Journal | 1993
Arie Zauberman; Yoav Barak; Ragimov N; Levy N; Moshe Oren
An immune selection procedure was employed in order to isolate p53 binding sites from mouse genomic DNA. Two DNA clones capable of tight specific interaction with wild type p53 were subjected to further characterization. In both cases, the p53 binding regions displayed a high degree of sequence homology with the consensus binding site defined for human genomic DNA. One of the clones was found to be derived from the LTR of a retrovirus‐like element (a member of the GLN family). The region encompassing the GLN LTR p53 binding site could confer p53 responsiveness upon a heterologous promoter. Furthermore, the expression of the endogenous, chromosomally integrated GLN elements was significantly induced upon activation of wild type p53 in cells harboring a temperature sensitive p53 mutant. Finally, it was demonstrated that p53 ‐ MDM2 complexes fail to bind tightly to such a p53 binding site. This may contribute to the inhibition by MDM2 of p53‐mediated transcriptional activation.
The EMBO Journal | 1998
Assaf Ori; Arie Zauberman; Gilad Doitsh; Nir Paran; Moshe Oren; Yosef Shaul
The transcription program of the hepatitis B virus (HBV) genome is regulated by an enhancer element that binds multiple ubiquitous and liver‐enriched transcription activators. HBV transcription and replication are repressed in the presence of p53. Here we describe a novel molecular mechanism that is responsible for this repression. The p53 protein binds to a defined region within the HBV enhancer in a sequence‐specific manner, and this, surprisingly, results in p53‐dependent transcriptional repression in the context of the whole HBV enhancer. This unusual behavior of the HBV enhancer can be reconstituted by replacing its p53‐binding region with the p53‐binding domain of the mdm2 promoter. Remarkably, mutation of the EP element of the enhancer reversed the effect of p53 from repression to transcriptional stimulation. Furthermore, EP‐dependent modulation of p53 activity can be demonstrated in the context of the mdm2 promoter, suggesting that EP is not only required but is also sufficient to convert p53 activity from positive to negative. Our results imply that the transcriptional effect of DNA‐bound p53 can be dramatically modulated by the DNA context and by adjacent DNA–protein interactions.
Immunology | 2001
Rachel Eren; Ido Lubin; Dov Terkieltaub; Ofer Ben-Moshe; Arie Zauberman; R Uhlmann; T Tzahor; S Moss; Daniel Shouval; E. Galun; Nili Daudi; Hadar Marcus; Yair Reisner; Shlomo Dagan
An approach to develop fully human monoclonal antibodies in a human/mouse radiation chimera, the Trimera system, is described. In this system, functional human lymphocytes are engrafted in normal strains of mice which are rendered immuno‐incompetent by lethal total body irradiation followed by radioprotection with severe combined immunodeficient (SCID) mouse bone marrow. Following transplantation, human lymphocytes colonize murine lymphatic organs and secrete human immunoglobulins. We have established this system as a tool to develop fully human monoclonal antibodies, and applied it for the generation of monoclonal antibodies specific for hepatitis B virus surface antigen. A strong memory response to hepatitis B surface antigen was elicited in Trimera engrafted with lymphocytes from human donors positive for antibodies to hepatitis B surface antigen. The human specific antibody fraction in the Trimera was 102–103‐fold higher as compared with that found in the donors. Spleens were harvested from Trimera mice showing high specific‐antibody titres and cells were fused to a human–mouse heteromyeloma fusion partner. Several stable hybridoma clones were isolated and characterized. These hybridomas produce high‐affinity, IgG, anti‐hepatitis B surface antigen antibodies demonstrating the potential of the Trimera system for generating fully human monoclonal antibodies. The biological function and the neutralizing activity of these antibodies are currently being tested.
Nucleic Acids Research | 2005
Sonia Schoonbroodt; Nicolas Frans; Mark DeSouza; Rachel Eren; Smadar Priel; Naama Brosh; Judith Ben-Porath; Arie Zauberman; Shlomo Dagan; Edward H. Cohen; Hennie R. Hoogenboom; Robert Charles Ladner; René Hoet
The use of oligonucleotide-assisted cleavage and ligation (ONCL), a novel approach to the capture of gene repertoires, in the construction of a phage-display immune antibody library is described. ONCL begins with rapid amplification of cDNA ends to amplify all members equally. A single, specific cut near 5′ and/or 3′ end of each gene fragment (in single stranded form) is facilitated by hybridization with an appropriate oligonucleotide adapter. Directional cloning of targeted DNA is accomplished by ligation of a partially duplex DNA molecule (containing suitable restriction sites) and amplification with primers in constant regions. To demonstrate utility and reliability of ONCL, a human antibody repertoire was cloned from IgG mRNA extracted from human B-lymphocytes engrafted in Trimera mice. These mice were transplanted with peripheral blood lymphocytes from Candida albicans infected individuals and subsequently immunized with C.albicans glyceraldehyde-3-phosphate dehydrogenase (GAPDH). DNA sequencing showed that ONCL resulted in efficient capture of gene repertoires. Indeed, full representation of all VH families/segments was observed showing that ONCL did not introduce cloning biases for or against any VH family. We validated the efficiency of ONCL by creating a functional Fab phage-display library with a size of 3.3 × 1010 and by selecting five unique Fabs against GAPDH antigen.
FEBS Letters | 1998
Gina Yardley; Arie Zauberman; Moshe Oren; Paul Jackson
The rat Cyclin G1 gene promoter contains one p53‐binding motif upstream of the transcription start site, and a second motif downstream in the first intron. We have investigated the possibility that these motifs co‐operate to permit high level promoter activation by p53. Although individual motifs supported p53‐dependent, orientation‐independent transcriptional activation, using reporter plasmids containing both motifs, we found no evidence for co‐operative promoter activation either after co‐transfection with human p53 expression plasmids, or after exposure of transfected cells to cisplatin and UV‐radiation.
Nucleic Acids Research | 1995
Arie Zauberman; Deborah Flusberg; Ygal Haupt; Yaacov Barak; Moshe Oren
Journal of Virology | 2006
Rachel Eren; Dorit Landstein; Dov Terkieltaub; Ofer Nussbaum; Arie Zauberman; Judith Ben-Porath; Judith Gopher; Rachel Buchnick; Riva Kovjazin; Ziva Rosenthal-Galili; Sigal Aviel; Yariv Shoshany; Lewis Neville; Tal Waisman; Ofer Ben-Moshe; Alberto Kischitsky; Steven K. H. Foung; Zhen-Yong Keck; Orit Pappo; Ahmed Eid; Oded Jurim; Gidi Zamir; Eithan Galun; Shlomo Dagan
The Journal of Infectious Diseases | 2002
Joseph Arazi; Ofer Nussbaum; Arie Zauberman; Rachel Eren; Ido Lubin; Lewis Neville; Ofer Ben-Moshe; Alberto Kischitzky; Amir Litchi; Ido Margalit; Judith Gopher; Samir Mounir; Weizhong Cai; Nili Daudi; Ahamed Eid; Oded Jurim; Abraham Czerniak; Eithan Galun; Shlomo Dagan
Hepatology | 2000
Rachel Eren; Ofer Nussbaum; Ido Lubin; Dov Terkieltaub; Yossi Arazi; Ofer Ben-Moshe; Alberto Kitchinzky; Shoshana Berr; Judy Gopher; Arie Zauberman; Eithan Galun; Danny Shouval; Nili Daudi; Ahamed Eid; Oded Jurim; Lars O. Magnius; Berit Hammas; Yair Reisner; Shlomo Dagan
Journal of Hepatology | 2007
Eithan Galun; Norah A. Terrault; Rachel Eren; Arie Zauberman; Ofer Nussbaum; Dov Terkieltaub; Meirav Zohar; Rachel Buchnik; Zvi Ackerman; Rifaat Safadi; Yaffa Ashur; Sara Misrachi; Yael Liberman; Ludmila Rivkin; Shlomo Dagan